Please upgrade your browser.
View expert presentations and download Powerpoint slides from this important kidney cancer meeting held recently in Budapest, Hungary.
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker.
AVEO Oncology and Astellas Pharma Inc. announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5% of all cases.
Surgery is the most common form of treatment for kidney tumors and often the only treatment necessary to achieve a cure.
TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annual Meeting
TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced multiple clinical investigations for TRC105 and the presentation of two abstracts at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 31 to June 4 in Chicago.
What remains in the pipeline of the eighth largest pharmaceuticals company after the recent approval of its last jackpot?
Specifically, the investigation concerns whether the Company misrepresented or failed to disclose that: (1) the FDA had recommended that the Company conduct an additional Phase III trial due to adverse trends in the Company's first Phase III trial; (2) there was a 25% higher rate of death associated with tivozanib therapy compared to the control drug, sorafenib; and (3) almost 90% of patients studied in the single Phase III trial were enrolled from sites in Central and Eastern Europe with inconsistent treatment patterns from those in the United States.
Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX™ in the treatment of metastatic renal cell carcinoma. Two patients with poor prognosis have thus far shown an average survival of about 11 months, which can be compared to the expected median survival of 5 months.
Search results on ASCO.org relating to abstracts presented at the 2013 Annual Meeting that are specific to kidney cancer.
|NeonCRM by Neon One|